Demodex Blepharitis

MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Jennifer M. Loh, MD, discusses how cases of Demodex blepharitis can sometimes masquerade as severe dry eye disease.

In this Healio Video Perspective, Bobak Azamian, MD, PhD, CEO and co-founder of Tarsus Pharmaceuticals, discusses topline data from the Saturn-2 phase 3 study of TP-03 for the treatment of Demodex blepharitis.

BOSTON – Most patients with Demodex blepharitis said the disease negatively affected their daily life in some way, with complaints such as ocular discomfort, difficulty driving at night and appearance, researchers reported here at the American Academy of Optometry annual meeting.

Tarsus Pharmaceuticals has completed enrollment in the second pivotal phase 3 trial investigating TP-03 for the treatment of Demodex blepharitis and secured a $175 million credit facility, according to a press release.

WAIKOLOA, Hawaii — In this video from Hawaiian Eye 2022, Bobak Azamien, MD, PhD, president and CEO of Tarsus Pharmaceuticals, discussed the company’s plans to move TP-03 toward FDA approval.

BOSTON – More than half of patients in six eye centers had collarettes, a clinical sign of Demodex blepharitis, on their eyelashes, according to a study presented here at the American Academy of Optometry meeting.

Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.

LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Ehsan Sadri, MD, FACS, discusses the prevalence of Demodex blepharitis in patients with dry eye disease.

In this Healio Video Perspective, Elizabeth Yeu, MD, FACS, takes a deep dive into the results of the Saturn-1 trial looking at TP-03 from Tarsus Pharmaceuticals for the treatment of Demodex blepharitis.

TP-03 met all primary and secondary endpoints in a phase 2b/3 trial and had no serious treatment-related adverse events or discontinuations in the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.